Get the Stockscreener App
23.33
0.98%
-0.22
Zymeworks Inc. stock is traded at $23.33, with a volume of 195.71K.
It is down -0.98% in the last 24 hours and down -12.95% over the past month.
Zymeworks Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The company's lead product candidate is ZW25, a novel bispecific antibody that is in Phase I clinical trial for the treatment of breast and gastric cancer. It is also developing ZW49, a bispecific antibody-drug conjugate that is in IND application stage. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Celgene Corporation and Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; and Janssen Biotech, Inc., as well as a collaboration agreement with Celgene Corporation. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies targeting cytokine-receptor pathways. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.
See More
Previous Close:
$23.55
Open:
$23.37
24h Volume:
195.71K
Relative Volume:
0.17
Market Cap:
$1.76B
Revenue:
$122.87M
Net Income/Loss:
$-73.68M
P/E Ratio:
-23.80
EPS:
-0.9803
Net Cash Flow:
$-39.27M
1W Performance:
-0.64%
1M Performance:
-12.95%
6M Performance:
+63.19%
1Y Performance:
+57.35%
1-Day Range:
$23.17
$23.76
1-Week Range:
$22.80
$24.31
52-Week Range:
$9.03
$28.49
Zymeworks Inc. Stock (ZYME) Company Profile
Name
Zymeworks Inc.
Sector
Industry
Phone
604-678-1388
Address
1385 West 8th Avenue, Suite 540, Vancouver, BC
Compare ZYME with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZYME
Zymeworks Inc.
|
23.31 | 1.78B | 122.87M | -73.68M | -39.27M | -0.9803 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.63 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.34 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
811.57 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
360.84 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.19 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Zymeworks Inc. Stock (ZYME) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-12-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-03-25 | Initiated | Citizens JMP | Mkt Outperform |
| Oct-24-25 | Resumed | Wells Fargo | Equal Weight |
| Oct-14-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-10-25 | Initiated | B. Riley Securities | Buy |
| May-20-25 | Initiated | TD Cowen | Buy |
| Dec-16-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Nov-07-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-01-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Mar-21-23 | Resumed | Wells Fargo | Overweight |
| Jan-04-23 | Reiterated | H.C. Wainwright | Neutral |
| Dec-20-22 | Upgrade | Jefferies | Hold → Buy |
| Nov-01-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-21-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Oct-04-22 | Resumed | Wells Fargo | Overweight |
| May-05-22 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-15-22 | Initiated | Evercore ISI | Outperform |
| Dec-10-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Nov-17-21 | Resumed | Guggenheim | Neutral |
| Oct-07-21 | Initiated | Jefferies | Hold |
| Mar-31-21 | Initiated | Credit Suisse | Outperform |
| Feb-25-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Feb-08-21 | Resumed | H.C. Wainwright | Buy |
| Jan-25-21 | Downgrade | Citigroup | Buy → Neutral |
| Sep-29-20 | Resumed | JP Morgan | Neutral |
| Aug-06-20 | Initiated | SVB Leerink | Outperform |
| Jan-10-20 | Initiated | Wolfe Research | Outperform |
| Dec-09-19 | Initiated | JP Morgan | Neutral |
| Nov-25-19 | Initiated | H.C. Wainwright | Buy |
| Nov-20-19 | Initiated | Guggenheim | Buy |
| Sep-30-19 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-30-19 | Initiated | Stifel | Buy |
| Jul-18-19 | Initiated | Deutsche Bank | Buy |
| May-11-18 | Upgrade | Barclays | Underweight → Equal Weight |
| Mar-19-18 | Initiated | Raymond James | Outperform |
View All
Zymeworks Inc. Stock (ZYME) Latest News
Analyst Upgrade: Does Zymeworks Inc have strong EBITDA marginsPortfolio Risk Summary & Reliable Breakout Stock Forecasts - baoquankhu1.vn
Analysts Are Bullish on Top Healthcare Stocks: Zymeworks (ZYME), Centessa Pharmaceuticals (CNTA) - The Globe and Mail
Zymeworks to Showcase Innovative Biotherapeutics at Upcoming Conferences - MSN
A Look At Zymeworks (ZYME) Valuation After Positive HERIZON GEA 01 Trial Results And Royalty Milestone Potential - Sahm
New Highs: Can Hippo Holdings Inc lead its sector in growthQuarterly Risk Review & Step-by-Step Trade Execution Guides - baoquankhu1.vn
Aug Analyst Calls: What is the earnings history of Zymeworks IncJuly 2025 Momentum & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Zymeworks (NYSE:ZYME) Shares Down 5.5%Here's Why - MarketBeat
Hollywood mark, EVP at Zymeworks, sells $138k in shares By Investing.com - Investing.com Nigeria
Zymeworks (NYSE:ZYME) COO Mark Hollywood Sells 6,120 Shares - MarketBeat
Hollywood mark, EVP at Zymeworks, sells $138k in shares - Investing.com
Zymeworks appoints industry veteran Brian Cherry to board By Investing.com - Investing.com Nigeria
Zymeworks Inc. (NASDAQ:ZYME) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Zymeworks (NYSE:ZYME) EVP Jeffrey Smith Sells 9,310 Shares - MarketBeat
Zymeworks (NYSE:ZYME) Insider Paul Andrew Moore Sells 9,560 Shares - MarketBeat
Zymeworks EVP Smith sells shares for $211,090 By Investing.com - Investing.com Canada
Zymeworks CSO Moore sells $216k in shares By Investing.com - Investing.com Nigeria
Zymeworks EVP Smith sells shares for $211,090 - Investing.com
Zymeworks CSO Moore sells $216k in shares - Investing.com
Insider Selling: Zymeworks (NYSE:ZYME) CEO Sells 30,424 Shares of Stock - MarketBeat
Zymeworks Announces Leadership Appointments and Transitions to Align with Evolution of Corporate Strategy - The Globe and Mail
What's Driving Zymeworks Stock Higher? - Nasdaq
Zymeworks Makes Leadership, Board Changes; Begins CFO Search - marketscreener.com
Zymeworks Reshapes Board and Executive Team to Support Next Phase of Growth - TipRanks
Zymeworks appoints industry veteran Brian Cherry to board - Investing.com
Zymeworks Inc. Announces Chief Financial Officer Changes - marketscreener.com
HERIZON-GEA-01 Trial Highlights Zymeworks’ Path To $440M Milestones And Growth (ZYME) - Seeking Alpha
Zymeworks (ZYME) Reports Positive Phase 3 Trial Results for Ziih - GuruFocus
Zymeworks reports positive phase 3 Ziihera data; cash runway extended beyond 2028 - Seeking Alpha
Zymeworks Sets 2026 Strategy on Zanidatamab Momentum, ADC Pipeline and Cash-Fueled Growth - TipRanks
Zymeworks Reports Positive Phase 3 Results for Ziihera® in HER2-Positive Gastroesophageal Adenocarcinoma, Announcing Strategic Priorities for 2026 - Quiver Quantitative
Zymeworks Outlines Strategic Priorities and Outlook for 2026 - The Manila Times
Zymeworks outlines strategic priorities and outlook for 2026 - marketscreener.com
Aug Macro: Is Zymeworks Inc. stock vulnerable to regulatory risksQuarterly Portfolio Summary & Reliable Breakout Stock Forecasts - ulpravda.ru
Can Zymeworks Inc. stock hit analyst price targetsWeekly Volume Report & Weekly Top Performers Watchlists - Улправда
Zymeworks Inc. (ZYME) Stock Analysis: A 53.85% Potential Upside In The Biotech Arena - DirectorsTalk Interviews
Earnings Beat: How Zymeworks Inc stock reacts to oil pricesJuly 2025 Analyst Calls & Safe Entry Trade Signal Reports - moha.gov.vn
How Zymeworks Inc. stock reacts to oil pricesShare Buyback & Weekly Stock Performance Updates - Улправда
Zymeworks (ZYME) Is Down 5.6% After Positive Phase 3 Ziihera Data Unlocks US$440 Million Milestones - simplywall.st
Will Zymeworks Inc. stock benefit from upcoming earnings reportsTrend Following Strategies & Affordable Trading Plans - ulpravda.ru
Oklahoma City NewsThe Oklahoman - FinancialContent
Jazz Pharmaceuticals' Drug Extends Survival Past Two Years in Advanced Stomach Cancer Trial - Benzinga
Q3 2025 Zymeworks Inc Earnings Call Transcript - GuruFocus
Jazz Pharmaceuticals' Drug Extends Survival Past Two Years in Advanced Stomach Cancer Trial - Sahm
Zymeworks Inc. (NYSE:ZYME) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Zymeworks’ Ziihera Sets New Survival Benchmark in First-Line HER2-Positive Gastric Cancer Trial - TipRanks
Zymeworks Reports Positive Phase 3 HERIZON-GEA-01 Results for Ziihera as Potential New Standard of Care in HER2-Positive First-Line Metastatic GEA - Quiver Quantitative
Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA including more than Two Years Median Overall Survival Benefit - GlobeNewswire
Redlands Daily Facts - FinancialContent
Zymeworks Inc. Stock (ZYME) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.38%
1.95%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):